Jeffrey Weber, MD, PhD, NYU Langone Medical Center, New York, NY, comments on the role of an ectoenzyme-expressing T cell population in immune checkpoint inhibitor (ICI) efficacy in patients with melanoma. These CD38+CD39+ T cells have found to have an immunosuppressive effect, and have additionally been identified as potential targets to enhance immune checkpoint blockade in patients. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.